AbstractMedical imaging by use of immunotargeting generally relies on a labeled molecule binding to a specific target on the cell surface. It is important to utilize both cell-based and time-resolved binding assays in order to understand the properties of such molecular interactions in a relevant setting.In this report we describe the detailed characterization of the interaction properties for AbD15179, a promising CD44v6-targeting antibody fragment for radio-immunotargeting. Influence of labeling and cell-line model on the protein interaction kinetics was assessed using three different labeling approaches (111In, 125I and FITC) on three different squamous carcinoma cell lines. Interactions were measured using time-resolved assays on living...
Abstract Molecular radiotherapy combines the advantages of systemic administration of highly specifi...
This thesis focuses on the evaluation of biomarkers for radio-immunodiagnostics and radio-immunother...
Rituximab is a monoclonal antibody drug approved for the treatment of patients with lymphomas. Ritux...
AbstractMedical imaging by use of immunotargeting generally relies on a labeled molecule binding to ...
AbstractIntroductionSelective tumor targeting strategies based on cell surface molecules enable new ...
Understanding molecular interactions on immune cells is crucial for drug development to treat cancer...
Monoclonal antibodies (mAbs) offer promise as effective tumor targeting and drug delivery agents for...
BACKGROUND: Patients with squamous cell carcinoma in the head and neck region (HNSCC) offer a diagno...
Antibody–drug conjugates (ADC) have shown promising effects in cancer therapy by combining the targe...
To personalize treatment for cancer, correct staging of the primary tumor, nodal disease and metasta...
Aim: The aim of this study was to generate and characterize scFv antibodies directed to human CD44v6...
We have developed the CD44v6-targeting human bivalent antibody fragment AbD19384, an engineered reco...
Reversible binding, for example between signaling molecules and receptors on the cell surface, is on...
The quantification of the number of targets in biological systems is an important parameter to asses...
Protein-protein interactions are crucial in numerous cellular functions and biological processes tha...
Abstract Molecular radiotherapy combines the advantages of systemic administration of highly specifi...
This thesis focuses on the evaluation of biomarkers for radio-immunodiagnostics and radio-immunother...
Rituximab is a monoclonal antibody drug approved for the treatment of patients with lymphomas. Ritux...
AbstractMedical imaging by use of immunotargeting generally relies on a labeled molecule binding to ...
AbstractIntroductionSelective tumor targeting strategies based on cell surface molecules enable new ...
Understanding molecular interactions on immune cells is crucial for drug development to treat cancer...
Monoclonal antibodies (mAbs) offer promise as effective tumor targeting and drug delivery agents for...
BACKGROUND: Patients with squamous cell carcinoma in the head and neck region (HNSCC) offer a diagno...
Antibody–drug conjugates (ADC) have shown promising effects in cancer therapy by combining the targe...
To personalize treatment for cancer, correct staging of the primary tumor, nodal disease and metasta...
Aim: The aim of this study was to generate and characterize scFv antibodies directed to human CD44v6...
We have developed the CD44v6-targeting human bivalent antibody fragment AbD19384, an engineered reco...
Reversible binding, for example between signaling molecules and receptors on the cell surface, is on...
The quantification of the number of targets in biological systems is an important parameter to asses...
Protein-protein interactions are crucial in numerous cellular functions and biological processes tha...
Abstract Molecular radiotherapy combines the advantages of systemic administration of highly specifi...
This thesis focuses on the evaluation of biomarkers for radio-immunodiagnostics and radio-immunother...
Rituximab is a monoclonal antibody drug approved for the treatment of patients with lymphomas. Ritux...